Alopecia

Given the distrust some patients with conditions such as alopecia areata and psoriasis have regarding JAK inhibitors, this analysis highlights several approaches to such concerns.

New data presented by Sun Pharma at EADV 2024 highlight the impact of deuruxolitinib 8 mg treatment of adults with severe alopecia areata.

These findings resulted from a systematic literature review highlighting the impact of stigma and lack of support on self-image for patients with eczema, psoriasis, HS, and other conditions.

A phase 2 trial shows tofacitinib improves autoimmune conditions in Down syndrome, with notable skin health benefits and a good safety profile.

Withdrawal of baricitinib in severe alopecia areata led to hair loss in 80% of patients, highlighting the need for ongoing therapy to maintain regrowth.

A new study revealed an increased risk of psychiatric and autoimmune comorbidities after an alopecia areata diagnosis.

Adults with severe alopecia were shown to have statistically significant efficacy across 2 phase 3 clinical studies highlighted in this announcement.

In this exclusive deep dive, a pair of leading dermatologists highlight the new data defining ruxotitinib cream, upadacitinib, and more agents from the revolutionary drug class.

A systematic review presented at AAPA 2024 showed insignificant differences in treatment outcomes between oral JAK inhibitors and oral steroids based on alopecia outcomes like SALT.

This analysis compared the efficacy of a 5 mg daily dose of oral minoxidil to topical minoxidil, 5%, among male alopecia patients.